Biocon
Ticker > Company >

Biocon share price

Biocon Ltd.

NSE: BIOCON BSE: 532523 SECTOR: Pharmaceuticals & Drugs  2.95 L   1.13 K   276

361.40
+7.00 (1.98%)
BSE: Today, 12:54 PM

Price Summary

Today's High

₹ 364.65

Today's Low

₹ 358.1

52 Week High

₹ 405.9

52 Week Low

₹ 290.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 48317.87 Cr.

Enterprise Value

₹ 50939.07 Cr.

No. of Shares

133.7 Cr.

P/E

80.52

P/B

3.04

Face Value

₹ 5

Div. Yield

0.14 %

Book Value (TTM)

₹  118.98

CASH

₹ 249.8 Cr.

DEBT

₹ 2871 Cr.

Promoter Holding

54.45 %

EPS (TTM)

₹  4.49

Sales Growth

5.42%

ROE

5.48 %

ROCE

6.57%

Profit Growth

410.73 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Biocon Ltd.

Insugen Basalog BIOMAb EGFR CANMAb ALZUMAb KRABEVA TACROGRAF

Index Presence

The company is present in 31Indices.

NFT150MOM50

Nifty Midcap150 Momentum 50
61465.25
  -187.199999999997 (-0.303637568336701%)

NIFTYMIDCAP

NIFTY Midcap 100
58775
  -73.5500000000029 (-0.124981838974803%)

NIFTY500

Nifty 500
23460
  14.7999999999993 (0.0631259276952179%)

NIFTYPHARMA

Nifty Pharma
22381.7
  140.350000000002 (0.631031839344298%)

NIFTYMIDCAP150

Nifty Midcap 150
21800.95
  -30.0999999999985 (-0.137877014619081%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20251.35
  -25.8000000000029 (-0.127236815824727%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18067.95
  -6.29999999999927 (-0.034856218100332%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
16465.75
  0.150000000001455 (0.000910990185598592%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16368.1
  1.45000000000073 (0.00885947949031962%)

NIFTYHEALTH

Nifty Healthcare Index
14723.65
  64.1000000000004 (0.437257623869769%)

NFT500EQUAL

Nifty 500 Equal Weight
14622.4
  -16.6000000000004 (-0.11339572375163%)

NIFTY200

Nifty 200
14162.25
  13.4500000000007 (0.0950610652493467%)

NIFTYTOTALMCAP

Nifty Total Market index
13205.75
  6.75 (0.0511402378968073%)

SHARIAH500

Nifty500 Shariah
7262
  4.5 (0.0620048225973058%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

NIFTY100ENHESG

NIFTY100 Enhanced ESG
5088.3
  14.75 (0.290723457933795%)

NIFTY100ESG

NIFTY100 ESG
5047.1
  14.0500000000002 (0.279154786858871%)

NIFTY100ESGSECT

Nifty100 ESG Sector Leaders
4268.25
  8.14999999999964 (0.191310063144057%)

MIDCAP

S&P Bse Mid Cap
46695.27
  -46.75 (-0.100017072432901%)

BSE HC

S&P Bse Healthcare
44793
  54.2699999999968 (0.121304292723545%)

BSE500

S&P Bse 500
36838.61
  25.4800000000032 (0.0692144351757129%)

MID150

S&P Bse 150 MidCap
16310.22
  -20.1200000000008 (-0.123206252901042%)

200EQW

BSE 200 Equal Weight
13184.46
  -8.34000000000015 (-0.0632162997998953%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12271.89
  -19.7100000000009 (-0.160353412086311%)

BSE200

S&P Bse 200
11514.2
  11.1200000000008 (0.0966697614899648%)

BSE1000

Bse 1000
10978.76
  6.53000000000065 (0.0595138818635821%)

LMI250

S&P Bse 250 LargeMidCap
10943.57
  11.2299999999996 (0.102722747371553%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year5.42%
3 Year8.86%
5 Year2.44%

Profit Growth

1 Year410.73%
3 Year91.99%
5 Year6.68%

ROE%

1 Year5.48%
3 Year12.29%
5 Year8.33%

ROCE %

1 Year6.57%
3 Year13.06%
5 Year9.12%

Debt/Equity

0.2515

Price to Cash Flow

77.44

Interest Cover Ratio

3.7898

CFO/PAT (5 Yr. Avg.)

0.339512120904757

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 54.45 0.00
Mar 2025 60.64 0.00
Dec 2024 60.64 0.00
Sep 2024 60.64 0.00
Jun 2024 60.64 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.196039556293729.
  • The company has an efficient Cash Conversion Cycle of 51.5048 days.
  • The company has a high promoter holding of 54.45%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 52.3903505659563.

 Limitations

  • The company has shown a poor revenue growth of 8.86384148721435% for the Past 3 years.
  • The company is trading at a high PE of 80.52.
  • The company is trading at a high EV/EBITDA of 121.1277.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 510.6 525.4 562.8 643.8 537.1
Total Expenditure 465.7 487.8 531.5 581.8 516.5
Operating Profit 44.9 37.6 31.3 62 20.6
Other Income 41.9 73.5 64.2 62.7 61.3
Interest 55.2 59.7 65.3 56.7 56.2
Depreciation 30.5 30.5 33.8 33 33.3
Exceptional Items 0 0 607.5 0 0
Profit Before Tax 1.1 20.9 603.9 35 -7.6
Tax 0.2 17.7 19.9 13.8 0.7
Profit After Tax 0.9 3.2 584 21.2 -8.3
Adjusted EPS (Rs) 0.01 0.03 4.86 0.18 -0.06

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2028.4 1738.2 1992.9 2127.3 2242.6
Total Expenditure 1717.2 1677.1 1972.1 1911.6 2079.9
Operating Profit 311.2 61.1 20.8 215.7 162.7
Other Income 151.5 187.2 274.1 240 255.4
Interest 0.4 0.4 69.6 198.8 236.9
Depreciation 103.5 108.2 116.9 121.1 127.8
Exceptional Items 0 0 2862.8 14.5 607.5
Profit Before Tax 358.8 139.7 2971.2 150.3 660.9
Tax 78.3 53.6 122.8 31 51.6
Net Profit 280.5 86.1 2848.4 119.3 609.3
Adjusted EPS (Rs.) 2.34 0.72 23.72 0.99 5.08

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 600 600.3 600.3 600.3 600.3
Total Reserves 7307.1 7492.6 10315.7 10312 10924.1
Borrowings 0 75.9 1297.7 2040.8 2251.5
Other N/C liabilities -30 -10.7 95.4 116.5 108
Current liabilities 550.2 590.9 698 691.2 1737.2
Total Liabilities 8427.3 8749 13007.1 13760.8 15621.1
Assets
Net Block 728.6 804.7 899.4 900.4 1059.5
Capital WIP 164.6 270.3 328.9 545 686.7
Intangible WIP 14.6 14.6 14.6 14.6 14.6
Investments 5073.4 5017.8 8949.8 9255.6 11382.6
Loans & Advances 150.5 154.2 159 204.1 238.4
Other N/C Assets 126.3 85.2 89.4 81.1 69.1
Current Assets 2169.3 2402.2 2566 2760 2170.2
Total Assets 8427.3 8749 13007.1 13760.8 15621.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 358.8 139.7 2971.2 150.3 660.9
Adjustment 117.8 108.3 -2726.9 112.3 -422.7
Changes in Assets & Liabilities 156 -172 16.1 -358.3 428.3
Tax Paid -61.3 -28.4 -41.1 -27.5 -42.6
Operating Cash Flow 571.3 47.6 219.3 -123.2 623.9
Investing Cash Flow -720.6 -302.1 -1173.1 -294.7 -991.5
Financing Cash Flow 27.8 112 1039.4 343.6 494.8
Net Cash Flow -121.5 -142.5 85.6 -74.3 127.2

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 60.64 60.64 60.64 60.64 54.45
dev mazumdar 0.08 0.08 0.08 0.08 0.07
glentec international 19.76 19.76 19.76 19.76 17.74
kiran mazumdar shaw 40.36 40.36 40.36 40.36 36.24
ravi rasendra mazumdar 0.44 0.44 0.44 0.44 0.40
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 39.36 39.36 39.36 39.36 45.55
beneficial holdings under... 0.46 0.46 0.46 0.46 0.41
icici prudential mutual f... - - - - 1.78
investor education and pr... 0.01 - 0.01 0.01 0.01
kotak equity opportunitie... 1.55 - - 1.28 1.36
lici child fortune plus g... 4.94 - - - 4.90
mirae asset multicap fund... - - - - 1.23
nippon life india trustee... - - - - 1.86
sbi magnum global fund - - - - 4.77
arun suresh chandavarkar 1.10 1.10 1.10 1.10 -
lici ulip-growth fund - 5.09 - 5.34 -
nippon life india trustee... - - - 1.25 -
sbi healthcare opportunit... - - 3.17 3.43 -
kotak balanced advantage ... - - 1.49 - -
life insurance corporatio... - - 5.34 - -
investor education and pr... - 0.01 - - -
kotak esg opportunities f... - 1.46 - - -
sbi arbitrage opportuniti... - 2.43 - - -
sbi contra fund 2.72 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INDIA RATINGS
Credit CRISIL
Credit FITCH
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit FITCH
Credit CRISIL
Credit ICRA
Credit ICRA
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit ICRA
Credit ICRA
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research Motilal Oswal
Research HDFC Securities
Research Motilal Oswal
Research Nirmal Bang
Research Hem Securities
Research ICICI Securities Limited
Research Geojit BNP Paribas

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY21
Concall Q3 FY20
Concall Q2FY24
Concall Q2FY23
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY24
Concall Q1FY21
Concall Q1FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY22
Presentation Q3FY22
Presentation Q3FY22
Presentation Q3FY22
Presentation Q3FY21
Presentation Q3 FY20
Presentation Q2FY24
Presentation Q2FY24
Presentation Q1FY25
Presentation Q1FY23
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY20

Company News

Biocon’s arm gets USFDA’s nod for Bosaya, Aukelso 18 Sep, 10:12 AM Biocon inaugurates first U.S. manufacturing facility in New Jersey 11 Sep, 9:39 AM Biocon informs about press release 11 Sep, 9:32 AM USFDA completes routine cGMP inspection at Bengaluru facility of Biocon’s arm 5 Sep, 10:13 AM Biocon’s arm receives tentative approval from USFDA for Sitagliptin Tablets USP 28 Aug, 9:39 AM Biocon informs about informs about presentation of earnings call 8 Aug, 10:05 AM Biocon gets nod to enter into agreements with Pro-zeal Green Power Sixteen 8 Aug, 10:00 AM Biocon reports 90% fall in Q1 consolidated net profit 8 Aug, 9:27 AM Biocon - Quaterly Results 7 Aug, 8:14 PM Biocon - Quaterly Results 7 Aug, 8:14 PM Biocon’s arm launches Nepexto in Australia 23 Jul, 11:19 AM Biocon informs about company statement 23 Jul, 9:43 AM Biocon informs about AGM 17 Jul, 4:55 PM Biocon’s arm gets USFDA’s nod for Kirsty 16 Jul, 10:22 AM Biocon’s arm receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars 7 Jul, 9:50 AM Biocon informs about press release 7 Jul, 9:43 AM Biocon’s arm receives marketing authorisation for Vevzuo and Evfraxy in EU 3 Jul, 11:10 AM Biocon informs about press release 30 Jun, 10:30 AM Biocon’s arm expands insulin access in Malaysia 30 Jun, 9:39 AM Biocon’s arm receives NOC from Health Canada for Yesafili 27 Jun, 10:42 AM Biocon informs about press release 27 Jun, 9:46 AM Biocon informs about communication to shareholders 26 Jun, 10:09 AM Biocon’s arm partners with National Cancer Society of Malaysia 24 Jun, 10:36 AM Biocon informs about press release 24 Jun, 9:41 AM Biocon informs about credit rating 18 Jun, 9:33 AM Biocon to raise up to Rs 4,500 crore via QIP 17 Jun, 11:08 AM Biocon informs about outcome of board meeting 16 Jun, 12:08 PM Biocon gets approval for diabetes drug Liraglutide in India 3 Jun, 12:22 PM Biocon’s arm receives MHRA, UK approval for YESINTEK, Biosimilar Ustekinumab 26 May, 9:59 AM Biocon informs about company statement 22 May, 12:59 PM Biocon informs about corporate presentation 12 May, 11:23 AM Biocon reports two-fold jump in Q4 consolidated net profit 9 May, 2:41 PM Biocon informs about investor presentation 9 May, 10:00 AM Biocon - Quaterly Results 8 May, 7:37 PM Biocon - Quaterly Results 8 May, 7:37 PM Biocon informs about press release 5 May, 9:58 AM Biocon’s arm secures multiple market access agreements for Yesintek 5 May, 9:28 AM Biocon informs about company statement 26 Apr, 12:23 PM Biocon gets nod to raise Rs 4,500 crore 24 Apr, 9:40 AM Biocon raises Rs 600 crore through commercial papers 23 Apr, 10:28 AM Biocon's arm inks settlement and license agreement with Regeneron 15 Apr, 12:51 PM Biocon informs about press release 15 Apr, 9:43 AM Biocon’s US arm recalling 2,184 bottles of medication to treat high cholesterol 11 Apr, 3:29 PM Biocon’s arm gets USFDA’s nod for Everolimus Tablets 11 Apr, 10:22 AM Biocon informs about press release 10 Apr, 9:41 AM Biocon’s arm gets USFDA’s approval for Jobevne 10 Apr, 9:11 AM Biocon gets nod to raise up to Rs 600 crore through commercial papers 5 Apr, 12:30 PM Biocon’s arm gets USFDA’s nod for Norepinephrine Bitartrate Injection 24 Mar, 11:55 AM Biocon informs about disclosure 24 Mar, 9:50 AM Biocon’s arm enters into strategic collaboration agreement with Civica 7 Mar, 9:36 AM

Biocon Stock Price Analysis and Quick Research Report. Is Biocon an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Biocon. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Biocon has a PE ratio of 80.3832015149827 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Biocon has ROA of 4.1475% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Biocon has a Current ratio of 1.2493.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Biocon has a ROE of 5.4777%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Biocon has a Debt to Equity ratio of 0.2515 which means that the company has low proportion of debt in its capital.

  • Sales growth: Biocon has reported revenue growth of 5.42% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Biocon for the current financial year is 7.25497190760723%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Biocon is Rs 0.5 and the yield is 0.1411%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Biocon is Rs 4.4885. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Biocon in Ticker for free. Also, one can get the intrinsic value of Biocon by using Valuation Calculators, which are available with a Finology ONE subscription. 

Biocon FAQs

Q1. What is Biocon share price today?
Ans: The current share price of Biocon is Rs 360.8.

Q2. What is the market capitalisation of Biocon?
Ans: Biocon has a market capitalisation of Rs 48237.6479508 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Biocon?
Ans: The PE ratio of Biocon is 80.3832015149827 and the P/B ratio of Biocon is 3.03238380834796, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Biocon share?
Ans: The 52-week high share price of Biocon is Rs 406, and the 52-week low share price of Biocon is Rs 291.

Q5. Does Biocon pay dividends?
Ans: Currently, Biocon pays dividends. Dividend yield of Biocon is around 0.1411%.

Q6. What are the face value and book value of Biocon shares?
Ans: The face value of Biocon shares is Rs 5, while the book value per share of Biocon is around Rs 118.9823. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Biocon?
Ans: Biocon has a total debt of Rs 2871 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Biocon?
Ans: The ROE of Biocon is 5.4777% and ROCE of Biocon is 6.5661%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Biocon a good buy for the long term?
Ans: The Biocon long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Biocon undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Biocon appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Biocon’s financials?
Ans: You can review Biocon’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Biocon

Biocon Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Biocon Ltd. is a leading biopharmaceutical company in India that specializes in the development and manufacturing of biosimilars, novel biologics, and complex small molecules.  We will provide a comprehensive stock analysis of Biocon Ltd. for long-term stock investors.

Biocon Ltd. Share Price 

Biocon's share price has been performing well in recent years, with a steady growth trend. The company's share price is influenced by various factors such as market conditions, industry trends, and company-specific news. Ticker pre-built screening tools can help you keep track of Biocon's share price and compare it with its peers.

Biocon Ltd. Balance Sheet 

Biocon's balance sheet provides insights into the company's financial health and its ability to meet its financial obligations. Our premium features, such as DCF Analysis, BVPS Analysis, and DuPont analysis, can help you calculate the fair value of Biocon's stock based on its balance sheet. By analyzing the company's assets, liabilities, and equity, you can gain a better understanding of its financial position and make informed investment decisions.

Biocon Ltd. Annual Report 

Biocon's annual report provides a comprehensive overview of the company's financial performance, business strategy, and future outlook. You can download Biocon's annual reports from Ticker and analyze them to gain insights into the company's operations and growth prospects. 

Biocon Ltd. Dividend 

Biocon has a consistent track record of paying dividends to its shareholders. The company's dividend payout ratio and yield can provide insights into its financial health and growth prospects. By analyzing Biocon's dividend history and payout policies, you can make informed decisions about investing in the company's stock.

Biocon Ltd. Quarterly Results 

Biocon's quarterly results provide insights into its financial performance and growth prospects. Our premium features, such as earnings multiple approach and DuPont analysis, can help you analyze Biocon's quarterly results and calculate its fair value. By comparing Biocon's quarterly results with its peers and tracking its progress over time, you can make informed investment decisions.

Biocon Ltd. Stock Price 

Biocon's stock price is influenced by various factors such as market conditions, industry trends, and company-specific news. Our pre-built screening tools can help you keep track of Biocon's stock price and compare it with its peers. By analyzing Biocon's stock price trends and market conditions, you can make informed investment decisions.

Biocon Ltd. Price Chart 

Biocon's price chart provides a visual representation of its stock price trends over time. You can use our pre-built screening tools to analyze Biocon's price chart and compare it with its peers. By analyzing Biocon's price chart, you can gain insights into its stock price trends and make informed investment decisions.

Biocon Ltd. News 

Biocon's news provides insights into its business operations, growth prospects, and industry trends. You can use our pre-built screening tools to keep track of Biocon's news and analyze its impact on the company's stock price. By staying up-to-date with Biocon's news, you can make informed investment decisions.

Biocon Ltd. Concall Transcripts 

Biocon's concall transcripts provide insights into its management's views on the company's financial performance, business strategy, and future outlook. You can download Biocon's concall transcripts from Ticker and analyze them to gain insights into the company's operations and growth prospects. By analyzing Biocon's concall transcripts, you can make informed investment decisions.

Biocon Ltd. Investor Presentations 

Biocon's investor presentations provide insights into its business operations, growth prospects, and industry trends. You can download Biocon's investor presentations from Ticker and analyze them to gain insights into the company's operations and growth prospects. By staying up-to-date with Biocon's investor presentations, you can make informed investment decisions.

Biocon Ltd. Promoters 

Biocon's promoters are highly experienced professionals with a proven track record in the biopharmaceutical industry. By analyzing Biocon's promoters and their past performance, you can gain insights into the company's business operations and growth prospects. 

Biocon Ltd. Shareholders 

Biocon's shareholders are a diverse group of investors with different investment objectives and risk profiles. By analyzing Biocon's shareholders and their investment patterns, you can gain insights into the company's stock price trends and growth prospects.Ticker pre-built screening tools can help you compare Biocon's shareholders with its peers and track their progress over time.

Biocon Ltd. ROCE

The Return on Capital Employed (ROCE) is a fundamental financial ratio that measures a company's profitability and efficiency in utilizing its capital. Biocon Ltd.'s ROCE indicates how well the company generates profits from the capital employed in its operations. This ratio is obtained by dividing the company's operating profit by its capital employed. To view Biocon Ltd.'s ROCE data, refer to the financials table or ratio section on this page.

Biocon Ltd. EBITDA

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. Biocon Ltd.'s EBITDA reflects its operating performance by excluding non-operating expenses. EBITDA is a useful metric for comparing companies' profitability and efficiency. To access Biocon Ltd.'s EBITDA data, refer to the financials table or ratio section provided on this page.

Biocon Ltd. DPS

DPS refers to Dividends Per Share, which indicates the amount of money paid to shareholders for each share owned. Biocon Ltd.'s DPS measures the company's willingness and ability to distribute profits to its shareholders. Investors often consider DPS when evaluating the income potential of a stock. To find Biocon Ltd.'s DPS data, refer to the financials table or ratio section featured on this page.

Biocon Ltd. EPS

EPS, or Earnings Per Share, is a financial metric that shows the profitability of a company on a per-share basis. Biocon Ltd.'s EPS reveals the portion of its profit allocated to each outstanding share. This ratio is significant for investors as it helps determine the value of a stock and its potential for growth. To access Biocon Ltd.'s EPS data, refer to the financials table or ratio section provided above. 

Biocon's Reserves Stability

Biocon has consistently strengthened its financial position as seen in its reserves, from Rs 6,937.30 Cr in Mar 2020 incrementally rising to Rs 10,312 Cr by Mar 2024. This stability in reserves is a testament to Biocon's capability to reinvest and fund its operations effectively.

Biocon Balance Sheet and Borrowings Insight

From the balance sheet of Biocon, we observe minimal borrowings at Rs 0.70 Cr in Mar 2020, which sees a notable increase to Rs 2,040.80 Cr by Mar 2024. This strategic shift in leveraging for growth could indicate Biocon's proactive approach to capital financing.

Biocon's Asset Growth

The total assets of Biocon have shown a positive trajectory, climbing from Rs 8,131.30 Cr in Mar 2020 to Rs 13,760.80 Cr in Mar 2024. Investments experience a notable jump, with a highlight on Mar 2023's figure at Rs 8,949.80 Cr, reflecting Biocon's focus on long-term asset accumulation and potential growth avenues.

Current Assets Surge in Biocon

Biocon's liquidity appears robust with current assets expanding from Rs 2,083.70 Cr in Mar 2020 to Rs 2,760 Cr by Mar 2024, illustrating improved operational efficiency and asset management.

This analysis is based on Biocon's standalone balance sheet data, giving a snapshot of the company's financial standing without suggesting any investment action.

In the realm of stock analysis, integrating such financial evaluations with broader market indicators and sector performance, as well as analyzing NSE/BSE index trends, can enhance insights for investors and market spectators analyzing companies like Biocon.

Read More
X